{"id":991,"date":"2019-03-28T13:52:36","date_gmt":"2019-03-28T13:52:36","guid":{"rendered":"https:\/\/www.competitionlawyers.co.uk\/blog\/?p=991"},"modified":"2019-03-28T13:52:36","modified_gmt":"2019-03-28T13:52:36","slug":"provisional-finding-in-hydrocortisone-competition-case","status":"publish","type":"post","link":"https:\/\/www.competitionlawyers.co.uk\/blog\/provisional-finding-in-hydrocortisone-competition-case","title":{"rendered":"Provisional finding in hydrocortisone competition case"},"content":{"rendered":"

There\u2019s been a provisional finding by the Competition and Markets Authority (CMA) in the important hydrocortisone competition case, with a Statement of Objections issued.<\/p>\n

In the coming weeks, the CMA expect written and oral representations to be made following the Statement of Objections that\u2019s been issued.<\/p>\n

The provisional findings of the CMA are incredibly worrying. It all comes down whether the two companies at the heart of the investigation colluded in order to charge higher prices and make bigger profits; all at the expense of our NHS, and our hard-earned tax money.<\/p>\n

<\/p>\n

Latest findings in the hydrocortisone competition case<\/strong><\/h3>\n

The latest provisional findings in the hydrocortisone competition case are damning. Auden Mckenzie (the only supplier of hydrocortisone tablets in the UK) and Waymade (their rival) are accused of breaking important competition laws<\/strong><\/a> between July 2011 and August 2015.<\/p>\n

Here\u2019s what we know so far about the provisional findings and the allegations that have been made:<\/p>\n